National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Atezolizumab (Tecentriq®) for adjuvant treatment of NSCLC. HTA ID: 22036

Atezolizumab is indicated as an adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells and who do not have EGFR mutant or ALK-positive NSCLC.

 

NCPE Assessment Process Complete
Rapid review commissioned 18/05/2022
Rapid review completed 02/06/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard-of-care.